A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of
sildenafil 50 & 100 mg added to stable antipsychotic treatment in schizophrenia patients to
assess whether this PDE5 inhibitor improves cognitive functioning (including verbal memory,
fluency, attention, spatial memory, motor speed, and executive function) and clinical
symptoms (psychotic, negative, mood symptoms, and self-reports of side-effects).